Fibroblast growth factors (FGFs) and their receptors (FGFRs) have been extensively investigated in solid malignancies, representing an attractive therapeutic target. In breast cancer, especially in estrogen receptor positive (ER+) subtype, FGFR signaling aberrations have been reported to contribute to proliferation, dedifferentiation, metastasis and drug resistance. However, clinical trials evaluating the use of FGFR inhibitors in breast cancer have had disappointing results. The different biological properties of distinct FGFR alterations and lack of established patient selection criteria, in addition to the early use of non-selective inhibitors, are possible reasons of this failure. Herein, we review the current knowledge regarding the role of FGFR signaling in endocrine resistance in breast cancer. We will also summarize the results from the clinical development of FGFR inhibitors in breast cancer, discussing future challenges to identify the correct cohorts of patients to enroll in trials testing FGFR inhibitors.
FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors / Servetto, A.; Formisano, L.; Arteaga, C. L.. - In: BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER. - ISSN 0304-419X. - 1876:2(2021), p. 188595. [10.1016/j.bbcan.2021.188595]
FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors
Servetto A.Primo
;Formisano L.;
2021
Abstract
Fibroblast growth factors (FGFs) and their receptors (FGFRs) have been extensively investigated in solid malignancies, representing an attractive therapeutic target. In breast cancer, especially in estrogen receptor positive (ER+) subtype, FGFR signaling aberrations have been reported to contribute to proliferation, dedifferentiation, metastasis and drug resistance. However, clinical trials evaluating the use of FGFR inhibitors in breast cancer have had disappointing results. The different biological properties of distinct FGFR alterations and lack of established patient selection criteria, in addition to the early use of non-selective inhibitors, are possible reasons of this failure. Herein, we review the current knowledge regarding the role of FGFR signaling in endocrine resistance in breast cancer. We will also summarize the results from the clinical development of FGFR inhibitors in breast cancer, discussing future challenges to identify the correct cohorts of patients to enroll in trials testing FGFR inhibitors.File | Dimensione | Formato | |
---|---|---|---|
Servetto A et al. FGFR signaling in breast cancer. BBA Reviews on cancer 2021.pdf
non disponibili
Licenza:
Non specificato
Dimensione
3.92 MB
Formato
Adobe PDF
|
3.92 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.